Navidea Biopharmaceuticals (NAVB +3.2%) moves up today after pricing its 1.54M shares secondary offering at $3.10 per share, just a penny shy of yesterday's close. The gross proceeds of sale total approximately $4.8M, and the company plans to use the proceeds to fund it's ongoing operations.
From other sites
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs